Arm A: E-T-CMF N = 333 | Arm B: E-CMF-wD N = 331 | Arm C: E-CMF-wT N = 326 | Total study population N = 990 | |
---|---|---|---|---|
Age | ||||
Median (range) | 53 (28-79) | 53 (21-78) | 54 (23-78) | 53 (21-79) |
N (%) | N (%) | N (%) | N (%) | |
Menopausal status | ||||
Premenopausal | 155 (46.5) | 157 (47.4) | 149 (45.7) | 461 (46.6) |
Postmenopausal | 178 (53.5) | 174 (52.6) | 177 (54.3) | 529 (53.4) |
Surgery | ||||
MRM | 167 (50.2) | 163 (49.2) | 175 (53.7) | 505 (51.0) |
Partial mastectomy | 166 (49.8) | 168 (50.8) | 151 (46.3) | 485 (49.0) |
Tumor size | ||||
≤2 | 159 (47.7) | 139 (42.0) | 119 (36.5) | 417 (42.1) |
2.1-5 | 155 (46.5) | 169 (51.1) | 183 (56.1) | 507 (51.2) |
>5 | 19 (5.7) | 23 (6.9) | 24 (7.4) | 66 (6.7) |
Positive nodes | ||||
0 | 83 (24.9) | 80 (24.2) | 83 (25.5) | 246 (24.8) |
1-3 | 136 (40.8) | 136 (41.1) | 136 (41.7) | 408 (41.2) |
≥4 | 114 (34.2) | 115 (34.7) | 107 (32.8) | 336 (33.9) |
Histological grade | ||||
1 | 25 (7.5) | 16 (4.8) | 20 (6.1) | 61 (6.2) |
2 | 155 (46.5) | 141 (42.6) | 152 (46.6) | 448 (45.3) |
3 | 153 (45.9) | 174 (52.6) | 154 (47.2) | 481 (48.6) |
Histological type | ||||
Invasive ductal NOS | 274 (82.3) | 273 (82.5) | 279 (85.6) | 826 (83.4) |
Invasive lobular | 31 (9.3) | 28 (8.5) | 22 (6.7) | 81 (8.2) |
Mixed type | 18 (5.4) | 18 (5.4) | 11 (3.4) | 47 (4.7) |
Medullary | 6 (1.8) | 6 (1.8) | 4 (1.2) | 16 (1.6) |
Mucinous | 2 (0.6) | 1 (0.3) | 2 (0.6) | 5 (0.5) |
Papillary | 1 (0.3) | 3 (0.9) | 3 (0.9) | 7 (0.7) |
Tubular | - | - | 1 (0.3) | 1 (0.1) |
Apocrine | - | 1 (0.3) | 1 (0.3) | 2 (0.2) |
Metaplastic | - | 1 (0.3) | - | 1 (0.1) |
Neuroendocrine | - | - | 1 (0.3) | 1 (0.1) |
Myeloepithelioma | - | - | 1 (0.3) | 1 (0.1) |
Other | 1 (0.3) | - | 1 (0.3) | 2 (0.2) |
Hormone receptor status | ||||
Negative | 74 (22.2) | 74 (22.4) | 71 (21.8) | 219 (22.1) |
Positive | 259 (77.8) | 257 (77.6) | 255 (78.2) | 771 (77.9) |
HER2 overexpression | ||||
No | 239 (71.8) | 240 (72.5) | 237 (72.7) | 716 (72.3) |
Yes | 94 (28.2) | 91 (27.5) | 89 (27.3) | 274 (27.7) |
Triple-negative | ||||
No | 292 (87.7) | 288 (87.0) | 291 (89.3) | 871 (88.0) |
Yes | 41 (12.3) | 43 (13.0) | 35 (10.7) | 119 (12.0) |
Post-chemotherapy treatment | ||||
Adjuvant hormonal therapy | ||||
No | 83 (24.9) | 85 (25.7) | 83 (25.5) | 251 (25.4) |
Yes | 250 (74.1) | 246 (74.3) | 243 (74.5) | 739 (74.6) |
Tamoxifen | 122 (36.6) | 113 (34.1) | 105 (32.2) | 340 (34.3) |
LH-RH | 101 (30.3) | 94 (28.4) | 97 (29.8) | 292 (29.5) |
Aromatase inhibitor | 150 (45.0) | 152 (45.9) | 163 (50.0) | 465 (47.0) |
Fulvestrant | 1 (0.3) | 1 (0.3) | 1 (0.3) | 3 (0.3) |
Adjuvant radiotherapy | ||||
No | 89 (26.7) | 95 (28.7) | 89 (27.3) | 273 (27.6) |
Yes | 244 (73.3) | 236 (71.3) | 237 (72.7) | 717 (72.4) |
Trastuzumab treatment | ||||
No | 243 (73.0) | 247 (74.6) | 245 (75.2) | 735 (74.2) |
Yes | 90 (27.0) | 84 (25.4) | 81 (24.8) | 255 (25.8) |